Targeting the mTOR pathway in Chromophobe Kidney Cancer
<p>Chromophobe kidney cancer accounts for approximately 5% of cases of renal cell carcinoma (RCC). While the genetics of clear cell RCC has been a major focus of research, little is known about the biology of chromophobe tumors. There is ample preclinical rationale for the use of targeted ther...
Main Author: | Brian Shuch, Srinivas Vourganti, Julia C. Friend, Lee M. Zehngebot, W. Marston Linehan, Ramaprasad Srinivasan |
---|---|
Format: | Article |
Language: | English |
Published: |
Ivyspring International Publisher
2012-01-01
|
Series: | Journal of Cancer |
Online Access: | http://www.jcancer.org/v03p0152.htm |
Similar Items
-
Targeting the mTOR pathway in breast cancer
by: Jia Liu, et al.
Published: (2017-06-01) -
mTOR signaling pathway and mTOR inhibitors in the treatment of cancer
by: Mehmet Küçüköner, et al.
Published: (2013-03-01) -
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
by: Zhilin Zou, et al.
Published: (2020-03-01) -
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
by: Tian Tian, et al.
Published: (2019-02-01) -
The role of mTOR pathway as target for treatment in adrenocortical cancer
by: Maria Cristina De Martino, et al.
Published: (2019-09-01)